NSCLC
Conditions
Brief summary
Study Arms: Patients receive autologous dendritic cells pulsed with antigen peptides ID on days 15, 29, 43,57,71,99,127and 155, and nivolumab IV over 60 minutes on days 15, 29, 43,57,71,85 99 and 113.
Detailed description
Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor-infiltrating effector T cells. DC vaccine may prime patients for treatments with immune checkpoint inhibitors by inducing effector T-cell infiltration into the tumors and immune checkpoint signals. The combination of DC vaccine and an immune checkpoint inhibitor may function synergistically to induce more effective antitumor immune responses, and clinical trials to test the combination are currently needed.
Interventions
DRUGAutologous dendritic cells pulsed with antigen
peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
Sponsors
Cttq
Henan Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Be 20 years of age or older on day of signing informed consent. 2. Non-small cell lung cancer (NSCLC) patient with progression on or after platinum-based chemotherapy. 3. Have measurable disease based on Response Evaluation in Solid Tumors (RECIST) 1.1. 4. Have a performance status of 0 - 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. 5. Life expectancy of \>6 months. 6. Females of childbearing potential should have a negative urine or serum pregnancy. 7. Serum glutamate pyruvate transaminase (SGPT) =\< 4.0 times upper limits of normal (ULN) 8. Serum glutamic-oxaloacetic transaminase (SGOT) =\< 4.0 times ULN 9. Creatinine =\< 2 times ULN 10. Patients who have one of the following HLA types: A2402, A0201, A0206 11. Pre-Leukaphersis evaluation 12. Hemoglobin \> 10 g/dL (100 g/L) 13. White blood cell count 3.0-11.0 x 10\^3/mm\^3 (3.0-11.0 x 10\^9/L) 14. Absolute granulocyte count \>= 1.5 x 10\^3/mm\^3 (1.5 x 10\^9/L) 15. Absolute lymphocyte count \>= 1.0 x 10\^3/mm\^3 (1.0 x 10\^9/L) 16. Platelet count \>= 100 x 10\^3/mm\^3 (100 x 10\^9/L)
Exclusion criteria
1. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. 2. Has a diagnosis of immunodeficiency or is receiving systemic steroid or any other form of immunosuppressive therapy. 3. Hypersensitivity to nivolumab or any of its excipients. 4. Has a known additional malignancy. 5. Any diagnosis of autoimmune disease. 6. Pregnant or breastfeeding within the projected duration of the trial, starting with screening visit through the last dose of trial treatment. 7. Positive HIV-1, -2, or HTLV-1, -2, tests. 8. Positive HBV or HCV tests. 9. Positive syphilis tests. 10. Recipient of organ allografts. 11. Inability or unwillingness to return for required visits and follow-up exams. 12. Acute infection: any active viral, bacterial, or fungal infection that requires specific therapy. 13. Active uncontrolled infection, such as a sexually transmitted disease (STD), herpes, uncontrolled tuberculosis, malaria, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | up to 2 year | From date of randomization until the date of first documented progression or date of death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | up to 1 year | From date of randomization until the date of death from any cause |
| Disease Control Rate (DCR) | up to 1 year | Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1. |
| Overall survival(OS) | up to 2 year | From date of randomization until the date of death from any cause |
Countries
China
Contacts
Primary ContactZibing Wang
Outcome results
None listed